Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

MLA

David Cella, et al. “Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following First-Line Sorafenib: Patient Reported Outcome Results across Two Phase III Studies (REACH-2 and REACH).” Annals of Oncology, vol. 29, Oct. 2018, p. viii208. EBSCOhost, https://doi.org/10.1093/annonc/mdy282.006.

APA

David Cella, Yanzhi Hsu, Josep M. Llovet, Masatoshi Kudo, Peter R. Galle, Andrew X. Zhu, Allicia C. Girvan, J.-F. Blanc, I. Chau, Paolo Abada, Richard S. Finn, Lee Bowman, Takuji Okusaka, & J. Gable. (2018). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). Annals of Oncology, 29, viii208. https://doi.org/10.1093/annonc/mdy282.006

Chicago

David Cella, Yanzhi Hsu, Josep M. Llovet, Masatoshi Kudo, Peter R. Galle, Andrew X. Zhu, Allicia C. Girvan, et al. 2018. “Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following First-Line Sorafenib: Patient Reported Outcome Results across Two Phase III Studies (REACH-2 and REACH).” Annals of Oncology 29 (October): viii208. doi:10.1093/annonc/mdy282.006.